Document Detail


Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort.
MedLine Citation:
PMID:  23032418     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To understand the HIV-hepatitis B virus (HBV) epidemic from a global perspective by clinically and virologically characterizing these viruses at the time of antiretroviral therapy (ART) initiation in a multinational cohort.
METHODS AND DESIGN: HIV-infected patients enrolled in two international studies were classified as HIV-HBV coinfected or HIV monoinfected prior to ART. HIV-HBV coinfected patients were tested for HBV characteristics, hepatitis D virus (HDV), a novel noninvasive marker of liver disease, and drug-resistant HBV. Comparisons between discrete covariates used χ or Fisher's exact tests (and Jonchkheere-Terpstra for trend tests), whereas continuous covariates were compared using Wilcoxon Rank-Sum Test.
RESULTS: Of the 2105 HIV-infected patients from 11 countries, the median age was 34 years and 63% were black. The 115 HIV-HBV coinfected patients had significantly higher alanine aminotransferase and aspartate aminotransferase values, lower BMI, and lower CD4 T-cell counts than HIV monoinfected patients (median 159 and 137 cells/μl, respectively, P = 0.04). In the coinfected patients, 49.6% had HBeAg-negative HBV, 60.2% had genotype A HBV, and 13% were HDV positive. Of the HBeAg-negative patients, 66% had HBV DNA 2000 IU/ml or less compared to 5.2% of the HBeAg-positive individuals. Drug-resistant HBV was not detected.
CONCLUSION: Screening for HBV in HIV-infected patients in resource-limited settings is important because it is associated with lower CD4 T-cell counts. In settings in which HBV DNA is not available, HBeAg may be useful to assess the need for HBV treatment. Screening for drug-resistant HBV is not needed prior to starting ART in settings in which this study was conducted.
Authors:
Chloe L Thio; Laura Smeaton; Melissa Saulynas; Hyon Hwang; Shanmugam Saravanan; Shanmugam Saravan; Smita Kulkarni; James Hakim; Mulinda Nyirenda; Hussain S Iqbal; Umesh G Lalloo; Anand S Mehta; Kimberly Hollabaugh; Thomas B Campbell; Shahin Lockman; Judith S Currier
Related Documents :
23527708 - High circulating chemokines (c-x-c motif) ligand 9, and (c-x-c motif) ligand 11, in hep...
23307058 - Spindle-shaped cd163+ rosetting macrophages replace cd4+ t-cells in hiv-related classic...
24252328 - Plasma cell disorders in hiv-infected patients: epidemiology and molecular mechanisms.
16567898 - Fatal isoflurane hepatotoxicity without re-exposure.
21503178 - Zero prevalence of parasites associated with oral lesions of hiv infected and aids pati...
12240878 - Simvastatin-induced rhabdomyolysis in an hiv-infected patient with coronary artery dise...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  AIDS (London, England)     Volume:  27     ISSN:  1473-5571     ISO Abbreviation:  AIDS     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2012-12-17     Completed Date:  2013-06-13     Revised Date:  2014-09-26    
Medline Journal Info:
Nlm Unique ID:  8710219     Medline TA:  AIDS     Country:  England    
Other Details:
Languages:  eng     Pagination:  191-201     Citation Subset:  IM; X    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antiretroviral Therapy, Highly Active / methods*
Antiviral Agents / therapeutic use*
CD4 Lymphocyte Count
Cohort Studies
Coinfection
Female
HIV Infections / complications*,  drug therapy
Hepatitis B / complications*,  drug therapy
Hepatitis B Surface Antigens
Humans
Male
Randomized Controlled Trials as Topic
Regression Analysis
Viral Load
Grant Support
ID/Acronym/Agency:
1U01AI069399-01/AI/NIAID NIH HHS; 1U01AI069401-01/AI/NIAID NIH HHS; 1U01AI069417-01/AI/NIAID NIH HHS; 1U01AI069421-01/AI/NIAID NIH HHS; 1U01AI069424-01/AI/NIAID NIH HHS; 1U01AI069426-01/AI/NIAID NIH HHS; 1U01AI069432-01/AI/NIAID NIH HHS; 1U01AI069436-01/AI/NIAID NIH HHS; 1U01AI069456-01/AI/NIAID NIH HHS; 1U01AI069463-01/AI/NIAID NIH HHS; 1U01AI069470/AI/NIAID NIH HHS; 1U01AI069471-01/AI/NIAID NIH HHS; 1U01AI069476-01/AI/NIAID NIH HHS; 1U01AI069495/AI/NIAID NIH HHS; 1U01AI069518-01/AI/NIAID NIH HHS; 5U01 AI069438/AI/NIAID NIH HHS; 5U01AI069438/AI/NIAID NIH HHS; AI 046376/AI/NIAID NIH HHS; AI050410/AI/NIAID NIH HHS; AI068636/AI/NIAID NIH HHS; AI069419/AI/NIAID NIH HHS; AI069423/AI/NIAID NIH HHS; AI069428/AI/NIAID NIH HHS; AI069471/AI/NIAID NIH HHS; AI069472-01/AI/NIAID NIH HHS; AI069474/AI/NIAID NIH HHS; AI069484-06/AI/NIAID NIH HHS; AI069513/AI/NIAID NIH HHS; AI25868/AI/NIAID NIH HHS; AI27661/AI/NIAID NIH HHS; AI32782/AI/NIAID NIH HHS; AI34853/AI/NIAID NIH HHS; AI38858-09S1/AI/NIAID NIH HHS; AI46370/AI/NIAID NIH HHS; AI46381/AI/NIAID NIH HHS; AI69450/AI/NIAID NIH HHS; AL-27665//PHS HHS; AL069532//PHS HHS; IAA#Y1-AI-8374-01/AI/NIAID NIH HHS; K24 AI56933/AI/NIAID NIH HHS; P30-AI-045008-12/AI/NIAID NIH HHS; R01 AI071820/AI/NIAID NIH HHS; R01 AI071820/AI/NIAID NIH HHS; R01CA120206/CA/NCI NIH HHS; R01CA136607/CA/NCI NIH HHS; RR 025747/RR/NCRR NIH HHS; RR024996/RR/NCRR NIH HHS; U01 AI068634/AI/NIAID NIH HHS; U01 AI068634/AI/NIAID NIH HHS; U01 AI068636/AI/NIAID NIH HHS; U01-A1 069424//PHS HHS; U01-AI-AI69467-05/AI/NIAID NIH HHS; U01-AI069439/AI/NIAID NIH HHS; U01AI068636/AI/NIAID NIH HHS; U01AI069511-02/AI/NIAID NIH HHS; UL1 RR 024160/RR/NCRR NIH HHS; UL1 TR000457/TR/NCATS NIH HHS
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Hepatitis B Surface Antigens
Comments/Corrections
Erratum In:
AIDS. 2013 Mar 27;27(6):1041
Note: Saravan, Shanmugam [corrected to Saravanan, Shanmugam]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Efficacy and immunogenicity of influenza vaccine in HIV-infected children: A randomized, double-blin...
Next Document:  Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected child...